ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2014
Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07761728 (Comparative Evaluation of 18F-Flurpiridaz and 82Rb-Chloride PET Myocardial Perfusion Imaging), which is not on this map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Evaluation of 18F-Flurpiridaz and 82Rb-Chloride PET Myocardial Perfusion Imaging: The FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial
Who cites it
42 citing papers in PubMed, 91 citations in OpenAlex.
- Utility ofCirculation. Cardiovascular imaging · 2025Trial
- Subendocardial quantification enhances coronary artery disease detection inEuropean journal of nuclear medicine and molecular imaging · 2025Trial
- Automatic motion correction for myocardial blood flow estimation improves diagnostic performance for coronary artery disease inJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2025Trial
- 18F-flurpiridaz positron emission tomography segmental and territory myocardial blood flow metrics: incremental value beyond perfusion for coronary artery disease categorization.European heart journal. Cardiovascular Imaging · 2022Trial
- Improved myocardial blood flow estimation with residual activity correction and motion correction inEuropean journal of nuclear medicine and molecular imaging · 2022Trial
- Added value of myocardial blood flow usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Trial
- Diagnostic Performance of PET Versus SPECT Myocardial Perfusion Imaging in Patients with Smaller Left Ventricles: A Substudy of theJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Evaluation of Myocardial Blood Flow UsingCurrent cardiology reports · 2026Review
- Dynamic frame-by-frame motion correction forEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Technical evaluation of immediate back-to-back rest-stress positron emission tomography scanning withJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2025Article
- The clinical promise ofNature cardiovascular research · 2025Article
- Expanding the repertoire ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2024Article
- Quantitative imaging for early detection and risk stratification of cardiovascular disease using 4D flow MRI and arterial spin labelling.Bioinformation · 2024Article
- Prevalence and nature of extracardiac findings in PET/CT myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Rest/stress myocardial perfusion imaging by positron emission tomography withJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Development, diagnostic performance, and interobserver agreement of aJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Automation in Nuclear Cardiology: Time for Flurpiridaz to Join the Club.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Anthracycline-induced cardiotoxicity: From pathobiology to identification of molecular targets for nuclear imaging.Frontiers in cardiovascular medicine · 2022Review
- Assessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- The "fixed" SPECT MPI defect: Where are we and where should we be going?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledAbsolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer.
methodsA new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress.
resultsIn healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with <50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with ≥50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between <50% and ≥50% stenosis vascular territories, were significant (P < 0.01).
conclusionAbsolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.